These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22111322)

  • 21. Hypertensive heart disease--significance of left ventricular hypertrophy.
    Schmieder RE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S50-5. PubMed ID: 1283190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications.
    Yiu KH; Tse HF
    J Hum Hypertens; 2008 Jun; 22(6):380-8. PubMed ID: 18337759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of sudden cardiac death in never previously treated patients with essential hypertension: long-term follow-up.
    Saadeh AM; Jones JV
    J Hum Hypertens; 2001 Oct; 15(10):677-80. PubMed ID: 11607796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Regression of left ventricular hypertrophy in hypertensive heart disease].
    Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
    Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertension and sudden cardiac death.
    Messerli FH
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):181S-188S. PubMed ID: 10619570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular structural changes in hypertension: possible regression during long-term antihypertensive treatment.
    Novo S; Abrignani MG; Corda M; Strano A
    Eur Heart J; 1991 Dec; 12 Suppl G():47-52. PubMed ID: 1839619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials.
    Moser M; Hebert PR
    J Am Coll Cardiol; 1996 Apr; 27(5):1214-8. PubMed ID: 8609345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
    Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J; Delpón E; Valenzuela C
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [High blood pressure and coronary heart disease. Are there new therapeutic options?].
    Motz W
    Herz; 2004 May; 29(3):255-65. PubMed ID: 15167951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
    Gustafsson F; Segura J; Ruilope LM
    J Hypertens; 2010 Aug; 28(8):1595-8. PubMed ID: 20613629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial fibrillation, the arrhythmia of the elderly, causes and associated conditions.
    Levy S
    Anadolu Kardiyol Derg; 2002 Mar; 2(1):55-60. PubMed ID: 12101796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.